The American Medical Association (AMA) has announced that, after assessing the proposed $69 billion merger between pharmacy benefit manager CVS Health and insurer Aetna, the organization is calling for regulators to block the transaction.
The American Medical Association (AMA) has announced that, after assessing the proposed $69 billion merger between pharmacy benefit manager (PBM) CVS Health and insurer Aetna, the organization is calling for regulators to block the transaction. The AMA has conducted an analysis of the merger since December 2017 and has sought the opinions and input of academic experts in health economics, health policy, and antitrust laws.
The president of the AMA, Barbara L. McAneny, MD, outlined the AMA’s reasoning behind the organization’s position in a hearing held by the California Department of Insurance. The position is based on evidence the AMA has found that the merger would have anticompetitive effects on Medicare Part D, PBM services, health insurance, retail pharmacy, and specialty pharmacy.
“After very careful consideration over the past months, the AMA has come to the conclusion that this merger would likely substantially lessen competition in many healthcare markets, to the detriment of patients,” said McAneny during her testimony. “The AMA is now convinced that the proposed CVS-Aetna merger should be blocked.”
The AMA will file a post-hearing memorandum compiling all of its concerns and the potential negative consequences of the merger; including an increase in premiums because of the consolidation in 30 Medicare Part D regional markets, an increase in drug spending and out-of-pocket costs for patients, a decrease in competition in health insurance markets, and the logistical difficulties of the merger.
In a statement to Forbes made yesterday, CVS said, “This combination does not further concentrate the healthcare sector; instead it reconfigures it to bring together disparate parts of the healthcare system that today lead to inefficient, ineffective, and more costly care.”
AMA, the nation’s largest physician association, looks to further address its concerns with federal and state regulators.
“Thanks to [California] Insurance Commissioner [David] Jones’ decision to hold this hearing, federal and state antitrust officials now have powerful reasons to block this harmful merger and foster a more competitive marketplace that will operate in patients’ best interest,” said the organization in a statement.
The AMA is not the first body to raise concerns about the deal, as the American Antitrust Institute (AAI) urged the Department of Justice (DOJ) to block the merger in March 2018, citing its belief that 3 integrated PBM-insurer systems would dominate the marketplace and effectively lock out competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.